depression MDD mood disorders depression depressive episode
Conditions
Interventions
Het doel van dit onderzoek is het vergelijken van drie verschillende methoden voor het bepalen van de individuele stimulusdrempel bij transcraniële magnetische stimulatie (TMS).Binnen de huidige klini
Sponsors
Universiteit van Tilburg
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers between 18-55 years old
Exclusion criteria
Exclusion criteria: Exclusion Criteria for Receiving TMS Participants will be excluded from the study if they meet any of the following criteria: 1. Neurological and Psychiatric Conditions: History of epilepsy or seizure disorders, Previous significant head trauma or traumatic brain injury with loss of consciousness >5 minutes. Presence of a known neurological disorder (e.g., stroke, multiple sclerosis, Parkinson*s disease, brain tumors). Current or past diagnosis of a severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, psychotic disorder). Current severe depression (e.g., suicidal ideation, recent hospitalization due to psychiatric reasons). History of substance use disorder within the past six months. 2. Medical Conditions and Contraindications: Presence of implanted metal objects or devices in or near the head (e.g., cochlear implants, deep brain stimulators, aneurysm clips, electrodes, metallic fragments). Pacemaker, defibrillator, or any other implanted electrical medical device. History of cardiac arrhythmias or other significant cardiovascular conditions. Uncontrolled hypertension. History of syncope or unexplained fainting episodes. 3. Medications and Substance Use: Use of medications known to lower seizure threshold (see list below). Recent use of recreational drugs or alcohol dependence. 4. Pregnancy and Hormonal Considerations: Current pregnancy Hormonal conditions that could influence cortical excitability (e.g., active hormone replacement therapy). 5. Other Exclusion Factors: Age below 18 or above 55 History of hypersensitivity or significant discomfort with previous TMS exposure. Participation in another clinical trial that may interfere with the results. Inability to provide informed consent or understand study procedures. Significant scalp abnormalities, infections, or skin conditions that could interfere with coil placement. History of migraine with aura (depending on severity and frequency). 6. Resting heart rate of 60BPM or less List of medication which exclude from this study: 1. Antipsychotics: • Clozapine • Chlorpromazine • Olanzapine • Haloperidol 2. Antidepressants: • Tricyclic antidepressants (TCAs): o Amitriptyline o Imipramine • Selective serotonin reuptake inhibitors (SSRIs): o Fluoxetine o Paroxetine • Bupropion 3. Mood Stabilizers: • Lithium 4. Stimulants: • Amphetamines (e.g., Adderall, Dexedrine) • Methylphenidate (e.g., Ritalin, Concerta) 5. Anesthetics and Analgesics: • Tramadol • Meperidine (Demerol) 6. Antibiotics: • Imipenem-cilastatin • Ciprofloxacin • Penicillins 7. Antihistamines: • Promethazine 8. Anti-malarial Drugs: • Chloroquine • Mefloquine 9. Theophylline: • Used for asthma and chronic obstructive pulmonary disease (COPD). 10. Illicit Substances: • Cocaine • Amphetamines • MDMA (Ecstasy)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main endpoint of the study is the difference between the three different methods in the established cortical threshold within each subject . | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint will be the amount of pain perceived within the FDA-approved protocol for MDD based on either 120% machine output based upon the EMG-MT or OM-MT. | — |
Countries
Netherlands
Contacts
Public ContactD. A. Timmers
Universiteit van Tilburg
Outcome results
None listed